| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 02/13/2003 | CA2455833A1 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists |
| 02/13/2003 | CA2455728A1 As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
| 02/13/2003 | CA2455235A1 1,2,4-triazin-3,5-diones as gonadotropin-releasing hormone receptor (gnrh) antagonists |
| 02/13/2003 | CA2455179A1 Androgen receptor modulators and methods of use thereof |
| 02/13/2003 | CA2454937A1 Modulators of notch signalling for use in immunotherapy |
| 02/13/2003 | CA2454159A1 Methods for assessing the risk of obesity based on allelic variations in the 5'-flanking region of the insulin gene |
| 02/13/2003 | CA2451868A1 Pharmaceutical composition comprising lipids comprising a polar and a nonpolar moiety |
| 02/13/2003 | CA2448235A1 Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins |
| 02/12/2003 | EP1283260A1 Novel insulin/igf/relaxin family polypeptides and dnas thereof |
| 02/12/2003 | EP1283216A1 Somatostatin analogues binding to all somatostatin receptor subtypes and their use |
| 02/12/2003 | EP1283209A1 Novel benzothiophene derivatives |
| 02/12/2003 | EP1283208A1 Novel benzofuran derivatives |
| 02/12/2003 | EP1282699A2 Splice-region antisense composition and method |
| 02/12/2003 | EP1282622A1 Crf receptor antagonists and methods relating thereto |
| 02/12/2003 | EP1282617A1 Hydantoin derivatives with affinity for somatostatin receptors |
| 02/12/2003 | EP1282615A1 Chroman derivatives as estrogenic compounds |
| 02/12/2003 | EP1282600A1 Inhibitors of dipeptidyl peptidase iv |
| 02/12/2003 | EP1282423A2 Prevention of insulin-dependent diabetes, complications thereof, or allograft rejection by inhibition of cyclooxygenase-2 activity with ns398 or pdtc |
| 02/12/2003 | EP1282418A2 Use of pyrazole derivatives for treating infertility |
| 02/12/2003 | EP1282416A2 Dehydroascorbic acid formulations and uses thereof |
| 02/12/2003 | EP1282410A2 Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists |
| 02/12/2003 | EP1282403A1 Non-invasive gene targeting to the brain |
| 02/12/2003 | EP1282400A2 Pharmaceutical form of administration for peptides, methods for its production and use |
| 02/12/2003 | EP1109534B1 Quick release pharmaceutical compositions of drug substances |
| 02/12/2003 | EP1104414B1 Enantioselective synthesis |
| 02/12/2003 | EP1042355B1 11beta-halogen-7alpha-substituted estratrienes, method for producing pharmaceutical preparations containing said 11beta-halogen-7alpha-substituted estratrienes and use of the same for producing medicaments |
| 02/12/2003 | EP1032584B1 Novel 19-nor steroids substituted in position 11beta, preparation method and intermediates, application as medicines and pharmaceutical compositions containing them |
| 02/12/2003 | EP0966299B1 Novel oral formulations of calcitonin |
| 02/12/2003 | CN1396915A Heterocylic derivative, its preparation method and medicine composition containing them |
| 02/12/2003 | CN1396912A 2-amino-nicotinamide derivative sand their use as VEGF-receptor tyrosine kinase inhibitors |
| 02/12/2003 | CN1396906A Calcilytic compounds |
| 02/12/2003 | CN1396823A Electrospun pharmaceutical compositions |
| 02/12/2003 | CN1395940A Chinese patent medicine for treating thyroidism and simple thyrocele and its preparing process |
| 02/12/2003 | CN1101228C Treatment of conditions and disease |
| 02/11/2003 | US6518277 Disrupting leukocyte function |
| 02/11/2003 | US6518264 For treatment/prevention of psychoses, other brain disorders, and cardiovascular disorders |
| 02/11/2003 | US6518257 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof |
| 02/11/2003 | US6518239 Dry powder compositions having improved dispersivity |
| 02/11/2003 | CA2174529C Dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5) and uses thereof |
| 02/11/2003 | CA2151564C Monomeric insulin analog formulations |
| 02/10/2003 | WO2002014320A2 Novel substituted diaryl azepine derivatives as integrin ligands |
| 02/10/2003 | CA2419078A1 Substituted diaryl azepine derivatives as integrin ligands |
| 02/06/2003 | WO2003010298A1 'probiotic lactobacillus salivarius strains |
| 02/06/2003 | WO2003009867A1 Use of biologically active hiv-1 tat, fragments or derivates thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases |
| 02/06/2003 | WO2003009807A2 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
| 02/06/2003 | WO2003009804A2 Conformationally constrained parathyroid hormone (pth) analogs |
| 02/06/2003 | WO2002079146A3 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 02/06/2003 | WO2002064586A3 Heterocyclic inhibitors of erk2 and uses thereof |
| 02/06/2003 | WO2002059112A3 Pyrazole compounds useful as protein kinase inhibitors |
| 02/06/2003 | WO2002039995A9 Combination therapy for estrogen-dependent disorders |
| 02/06/2003 | US20030028004 68730 and 69112, protein kinase molecules and uses therefor |
| 02/06/2003 | US20030027995 Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| 02/06/2003 | US20030027862 Amino-and amido-diphenyl ethers |
| 02/06/2003 | US20030027815 10-(4-cyclohexylbenzoyl)-10,11-dihydro-5H-pyrrolo(2,1-c)(1,4)b enzodiazepine derivatives, useful for suppression of disorders which may be remedied or alleviated by oxytocin antagonist activity, including premature labor |
| 02/06/2003 | US20030027752 Leucine-based motif and clostridial neurotoxins |
| 02/06/2003 | US20030027261 Novel genes TZap7/A, TZap7/B and TZap7 involved in T cell activation and uses thereof |
| 02/06/2003 | US20030027158 Novel nucleic acid sequences encoding human breast tumor-associated protein 47-like polypeptides |
| 02/06/2003 | CA2452159A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
| 02/05/2003 | EP1281709A1 Novel heterocyclic compounds with anti-inflammatory activity |
| 02/05/2003 | EP1281702A2 Calcium receptor active molecules |
| 02/05/2003 | EP1281399A2 Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production |
| 02/05/2003 | EP1280888A1 Cell culture method, cell cluster obtained by said methods and use thereof |
| 02/05/2003 | EP1280803A1 Crystalline form ii of cabergoline |
| 02/05/2003 | EP1280797A1 Inhibitors of dipeptidyl peptidase iv |
| 02/05/2003 | EP1280779A1 New polycyclic indanylimidazoles with alpha2 adrenergic activity |
| 02/05/2003 | EP1280533A2 Aldosterone antagonist composition for release during aldosterone acrophase |
| 02/05/2003 | EP1280518A2 Liposome drug delivery |
| 02/05/2003 | EP0871463B1 Regulation of eating behavior |
| 02/05/2003 | CN1395580A Human cystine knot polypeptide |
| 02/05/2003 | CN1395574A Food product and producing method |
| 02/05/2003 | CN1395566A Corticotropin releasing factor antagonists |
| 02/05/2003 | CN1395488A Drospirenone for hormone replacement therapy |
| 02/05/2003 | CN1395467A Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents |
| 02/05/2003 | CN1100542C Compositions containing at least one glucocoricoid in combination with pulmonary surfactant for treatment of IRDS and ARDS |
| 02/05/2003 | CN1100541C Therapeutic uses and delivery systems of dehydroepiandrosterone |
| 02/04/2003 | US6515117 C-aryl glucoside SGLT2 inhibitors and method |
| 02/04/2003 | US6515002 Compounds and compositions for treating C1s-mediated diseases and conditions |
| 02/04/2003 | US6514988 Condensed-ring thiophene derivatives, their production and use |
| 02/04/2003 | US6514982 CRF receptor antagonists and methods relating thereto |
| 02/04/2003 | US6514958 Dosage unit comprising tibolone and a water insoluble starch product is contained in a humid atmosphere of 50 to 70% relative humidity until administration |
| 02/04/2003 | US6514745 Oncoprotein protein kinase |
| 02/04/2003 | US6514491 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol) |
| 02/04/2003 | CA2271478C Tissue specific expression of retinoblastoma protein |
| 02/01/2003 | CA2395006A1 Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production |
| 01/31/2003 | WO2002012169A1 Amino diphenyl ethers and amido diphenyl ethers |
| 01/31/2003 | CA2417880A1 Amino diphenyl ethers and amido diphenyl ethers |
| 01/30/2003 | WO2003008633A1 Screening method using fish embryo |
| 01/30/2003 | WO2003008444A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | WO2003008443A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | WO2003008414A1 Chemical compounds |
| 01/30/2003 | WO2003008412A2 Hetero-bicyclic crf antagonists |
| 01/30/2003 | WO2003008407A2 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use |
| 01/30/2003 | WO2003007993A1 Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor |
| 01/30/2003 | WO2003007951A1 A synergistic pharmaceutical combination for the prevention or treatment of diabetes |
| 01/30/2003 | WO2003007689A2 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| 01/30/2003 | WO2002088079A3 Dual inhibitors of pde 7 and pde 4 |
| 01/30/2003 | WO2002072078A9 Use of sugar phosphates, amino acids, amino acid analogs, e.g. carbomethoxypropionyl cyanide for reducing weight or diabetes complications |
| 01/30/2003 | WO2002034200A3 Transdermal therapeutic systems comprising photosensitive active substances |
| 01/30/2003 | WO2002026215A3 Thermogelling biodegradable aqueous polymer solution |
| 01/30/2003 | WO2002010393A3 Isolated nucleic acid molecules which encode t cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof |